RJA
LMAT icon

Raymond James & Associates’s LeMaitre Vascular LMAT Stock Holding History

Raymond James & Associates’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.75M Buy
29,592
+748
+3% +$64.8K ﹤0.01% 2025
2024
Q2 		$2.37M Sell
28,844
-637
-2% -$46.8K ﹤0.01% 2055
2024
Q1 		$1.96M Buy
29,481
+1,356
+5% +$83.7K ﹤0.01% 2171
2023
Q4 		$1.6M Buy
28,125
+3,298
+13% +$173K ﹤0.01% 2232
2023
Q3 		$1.35M Buy
24,827
+967
+4% +$57.3K ﹤0.01% 2261
2023
Q2 		$1.61M Buy
23,860
+2,779
+13% +$170K ﹤0.01% 2196
2023
Q1 		$1.09M Buy
21,081
+1,539
+8% +$74.7K ﹤0.01% 2409
2022
Q4 		$899K Buy
19,542
+3,489
+22% +$163K ﹤0.01% 2491
2022
Q3 		$814K Buy
16,053
+1,543
+11% +$77.1K ﹤0.01% 2527
2022
Q2 		$661K Buy
14,510
+1,775
+14% +$79.4K ﹤0.01% 2728
2022
Q1 		$592K Sell
12,735
-1,721
-12% -$77K ﹤0.01% 2967
2021
Q4 		$726K Buy
14,456
+3,934
+37% +$203K ﹤0.01% 2835
2021
Q3 		$559K Buy
10,522
+686
+7% +$38.6K ﹤0.01% 2988
2021
Q2 		$600K Buy
9,836
+1,859
+23% +$98.8K ﹤0.01% 2955
2021
Q1 		$389K Buy
+7,977
New +$374K ﹤0.01% 3190
2020
Q4 		– Sell
-39,173
Closed -$1.27M – 3830
2020
Q3 		$1.27M Sell
39,173
-1,411
-3% -$42.4K ﹤0.01% 2026
2020
Q2 		$1.07M Sell
40,584
-379
-0.9% -$9.91K ﹤0.01% 2119
2020
Q1 		$1.02M Sell
40,963
-19,007
-32% -$587K ﹤0.01% 1964
2019
Q4 		$2.16M Buy
59,970
+31,378
+110% +$1.08M ﹤0.01% 1778
2019
Q3 		$977K Sell
28,592
-521
-2% -$16.6K ﹤0.01% 2215
2019
Q2 		$815K Buy
29,113
+1,661
+6% +$46.2K ﹤0.01% 2344
2019
Q1 		$851K Sell
27,452
-44
-0.2% -$1.17K ﹤0.01% 2299
2018
Q4 		$650K Buy
27,496
+2,201
+9% +$60.1K ﹤0.01% 2365
2018
Q3 		$980K Buy
25,295
+5,010
+25% +$181K ﹤0.01% 2271
2018
Q2 		$679K Buy
+20,285
New +$722K ﹤0.01% 2474
2017
Q4 		– Sell
-5,362
Closed -$201K – 3485
2017
Q3 		$201K Sell
5,362
-4,024
-43% -$137K ﹤0.01% 3044
2017
Q2 		$293K Sell
9,386
-89
-0.9% -$2.57K ﹤0.01% 2740
2017
Q1 		$233K Buy
+9,475
New +$222K ﹤0.01% 2833

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's LMAT Position: Q3 2024 in Review

Raymond James & Associates increased its LeMaitre Vascular (LMAT) stake by 2.6% in Q3 2024, buying an estimated $64.8K and bringing the position to 29,592 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

Raymond James & Associates first reported a position in LMAT in Q1 2017 and has held it in 28 quarters since. 291 funds tracked by Wall St. Rank hold LMAT as of Q3 2024.

  • Raymond James & Associates held 29,592 shares of LeMaitre Vascular worth $2.75M as of Q3 2024.
  • Raymond James & Associates bought 748 LeMaitre Vascular shares in Q3 2024, an estimated $64.8K.
  • LeMaitre Vascular made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2025 holding.
  • Raymond James & Associates first reported a position in LeMaitre Vascular in Q1 2017 and has held it in 28 quarters since.
  • 291 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.